How to use this tool
How to use this tool
InvestorGuide Stock Analysis
Upcoming Acquisition between Merck and Schering-Plough Appears Healthy
Excerpt from the InvestorGuide.com Stock of the Day on 10/22/2009
Since the beginning of this year, there has been a lot of attention given to drugmaker Merck & Co., ever since the company announced in March that they would be merging with Schering-Plough Corporation (SGP: Charts, News, Offers). The deal has been carefully analyzed, going through all the regular regulatory channels. And as the end of the year approaches, and the final stages of the deal loom just around the corner, the big question is: Are these two companies in good health as they head towards the merger, or could there be larger issues plaguing this arrangement? More >
Walgreen Receives a Shot of Success with Pharmaceuticals
Excerpt from the InvestorGuide.com Stock of the Day on 9/29/2009
The Walgreen Company beat out Wall Street predications with its fourth quarter performance today. Although profit declined from this time last year, it managed to top analysts' expectations. Walgreen also saw its overall sales rise 7.6 percent. The largest U.S. drugstore has been battling increasing competition from CVS (CVS: Charts, News, Offers) and Rite Aid (RAD: Charts, News, Offers), but its fourth quarter report comes as promising news for most investors. How was Walgreen able to post such an impressive quarterly performance? What are the drugstore chain's plans for the future? More >
Rite Aid Needs More Than a Band-Aid to Fix Its Problems
Excerpt from the InvestorGuide.com Stock of the Day on 9/24/2009
Just a little over two years ago, in June 2007, Rite Aid was sitting pretty. The company had just completed a major acquisition, making Rite Aid the third largest drug store, and had announced unexpectedly strong profits. Analysts thought they might be unstoppable, and that Rite Aid would be giving its competitors a run for their money. However, two years later, the company is in a much different position. What does the future look like for Rite Aid, and is there a prescription that can help this ailing company? More >
Excerpt from the InvestorGuide.com Stock of the Day on 10/22/2009
Since the beginning of this year, there has been a lot of attention given to drugmaker Merck & Co., ever since the company announced in March that they would be merging with Schering-Plough Corporation (SGP: Charts, News, Offers). The deal has been carefully analyzed, going through all the regular regulatory channels. And as the end of the year approaches, and the final stages of the deal loom just around the corner, the big question is: Are these two companies in good health as they head towards the merger, or could there be larger issues plaguing this arrangement? More >
Walgreen Receives a Shot of Success with Pharmaceuticals
Excerpt from the InvestorGuide.com Stock of the Day on 9/29/2009
The Walgreen Company beat out Wall Street predications with its fourth quarter performance today. Although profit declined from this time last year, it managed to top analysts' expectations. Walgreen also saw its overall sales rise 7.6 percent. The largest U.S. drugstore has been battling increasing competition from CVS (CVS: Charts, News, Offers) and Rite Aid (RAD: Charts, News, Offers), but its fourth quarter report comes as promising news for most investors. How was Walgreen able to post such an impressive quarterly performance? What are the drugstore chain's plans for the future? More >
Rite Aid Needs More Than a Band-Aid to Fix Its Problems
Excerpt from the InvestorGuide.com Stock of the Day on 9/24/2009
Just a little over two years ago, in June 2007, Rite Aid was sitting pretty. The company had just completed a major acquisition, making Rite Aid the third largest drug store, and had announced unexpectedly strong profits. Analysts thought they might be unstoppable, and that Rite Aid would be giving its competitors a run for their money. However, two years later, the company is in a much different position. What does the future look like for Rite Aid, and is there a prescription that can help this ailing company? More >
K-V Pharmaceutical Company (KV.A) Upgrades
Date
Analyst
Old Rating
New Rating
06/20/2007
Roth Capital
Hold
Buy
06/12/2007
JP Morgan
Neutral
Overweight
11/10/2005
Banc of America
Buy
N/A
K-V Pharmaceutical Company (KV.A) Downgrades
Date
Analyst
Old Rating
New Rating
12/24/2008
Gabelli & Co
Buy
Hold
06/17/2007
Roth Capital
Buy
Hold
06/16/2007
Roth Capital
Buy
Hold
06/15/2007
Roth Capital
Buy
Hold
K-V Pharmaceutical Company (KV.A) New Coverage
Date
Analyst
Rating
No new coverage listed for KV.A at this time.
Special Offers
| Buy stock for just $4 www.sharebuilder.com |
| Learn to spot opportunities in any market with a Risk-Free* 30-day trial from Investools. www.investools.com |
| Trade Forex with FXSolutions. Sign up for FREE $10,000 Practice Account. www.fxsolutions.com |
| Download a free Options Fundamentals Podcast, from The Options Industry Council. OptionsEducation.org |
KV.A Links
Guru Analysis:
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy KV.A for just $4
MSN Money | Morningstar | Stock Consultant
Analyst Opinions:
Reuters | SmartMoney | MarketWatch | Nasdaq | BarChart | Schaeffers | CNN Money | TheStreet
Blogs:
SocialPicks | Topix.net | SeekingAlpha | Technorati | Ask.com
Message Boards:
ClearStation | RagingBull | Yahoo | Investopedia | FreeRealTime | StockHouse Trading Offers:
Buy KV.A for just $4
